TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

• Status: Completed
• Trial end date: 2003-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, double-blind study of the tolerability of three different doses of rifapentine

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centers for Disease Control and Prevention
• Collaborators: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Rifampin; Rifapentine

Criteria

Inclusions:

1. Drug susceptible culture-positive tuberculosis

2. Adequate induction therapy

3. Age >18

4. Normal screening labs

5. Karnofsky >=60

6. Informed consent

7. Birth control if of child bearing potential

Exclusions:

1. SilicoTB

2. Skeletal or CNS TB

3. Pregnant or breastfeeding

4. Intolerance to INH or rifamycins

5. Over 70 days TB treatment just prior to enrollment